Skip to content
Screener

Alumis Inc. ALMS Return on equity

Return on equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
46.7%+17.8pp
Amgen logo
AmgenAMGN
91.5%-7.7pp
Immunome logo
ImmunomeIMNM
-50.1%-10.8pp
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
-27.3%-11.1pp
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-36.3%—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
21%+19.1pp

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.54B+686%
Enterprise value$3.52B+940%
P/S421.8×—

Profitability

See full
Operating margin-5,364%—
Net margin-2,825.7%—
FCF margin-4,487.4%—

Returns & leverage

See full
Debt / equity0.1×+0.1×
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

net income/total stockholders equity=-64.6%

Based on trailing twelve months.

The source filing: Alumis Inc.’s 10-Q, filed May 14, 2026. Open the filing →

Filed
May 14, 2026, 4:16 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001847367-26-000010

FAQ

What is Alumis Inc.'s return on equity?
Alumis Inc. (ALMS) reported return on equity of -64.6% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.

Ask your AI about Alumis Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude